Cover Image
市場調查報告書

何杰金氏淋巴瘤:開發平台分析

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232775
出版日期 內容資訊 英文 418 Pages
訂單完成後即時交付
價格
Back to Top
何杰金氏淋巴瘤:開發平台分析 Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017
出版日期: 2017年03月31日 內容資訊: 英文 418 Pages
簡介

何杰金氏淋巴瘤是淋巴系統組織的癌症之一,在淋巴節和脾臟,肝臟,骨髓等地方出現。患者的年齡層約15∼30歲,以及50∼70歲佔大半。部分病例,據信是因EB病毒(EBV)的感染經歷而發病。還有具HIV感染經歷比起普通人發病風險也變高。主要的症狀為伴隨頸部、腋下、鼠蹊部的淋巴節疼痛的腫脹,及發熱、發冷,盜汗,體重減輕,食慾衰退,皮膚發癢等。主要的治療方法,有外科手術和放射治療、化療等。

本報告提供全球各國的何杰金氏淋巴瘤治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

何杰金氏淋巴瘤概要

治療藥的開發

  • 何杰金氏淋巴瘤開發中產品:概要
  • 何杰金氏淋巴瘤開發中產品:比較分析

各企業開發中的何杰金氏淋巴瘤治療藥

大學/研究機關研究中的何杰金氏淋巴瘤治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

何杰金氏淋巴瘤治療藥:開發中的產品一覽(各企業)

何杰金氏淋巴瘤治療藥:研究中的產品一覽(各大學/研究機關)

何杰金氏淋巴瘤開發治療藥的企業

  • 4SC AG
  • Acetylon Pharmaceuticals, Inc.
  • Actinium Pharmaceuticals, Inc.
  • ADC Therapeutics Sarl
  • Affimed Therapeutics AG
  • Arbutus Biopharma Corporation
  • Bellicum Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cell Medica Limited
  • Cellular Biomedicine Group, Inc.
  • Constellation Pharmaceuticals, Inc.
  • Curis, Inc.
  • Faron Pharmaceuticals Oy
  • Fate Therapeutics, Inc.
  • Gamida Cell Ltd.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Merck & Co., Inc.
  • Mirati Therapeutics Inc.
  • Molecular Templates Inc.
  • NantKwest, Inc.
  • Novartis AG
  • 小野藥品工業
  • Pfizer Inc.
  • Pharmacyclics, Inc.
  • Philogen S.p.A.
  • Rich Pharmaceuticals, Inc.
  • Seattle Genetics, Inc.
  • Selvita S.A.
  • Sigma-Tau S.p.A.
  • Spectrum Pharmaceuticals, Inc.
  • Stemline Therapeutics, Inc.
  • Syndax Pharmaceuticals, Inc.
  • 武田藥品工業
  • TG Therapeutics, Inc.
  • Theravectys SA
  • Trillium Therapeutics Inc.

何杰金氏淋巴瘤:治療藥的評估

  • 單劑治療藥的情況
  • 組合產品
  • 各標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • (INCB-039110 + INCB-040093)
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • abexinostat hydrochloride
  • acalisib
  • ADCT-301
  • AFM-13
  • Alocrest
  • aNK Program
  • azacitidine
  • BMS-986016
  • BPX-501
  • burentsukishimabubedochin
  • CBM-C30.1
  • 何杰金氏病、非何杰金氏淋巴瘤的細胞免疫療法
  • 腫瘤學細胞免疫療法
  • 何杰金氏病、非何杰金氏淋巴瘤 CD30標的之細胞免疫療法
  • 何杰金氏淋巴瘤、慢性淋巴性白血病GM-CSF標的之細胞免疫療法
  • EB病毒相關腫瘤、感染疾病LMP/BARF-1/EBNA1標的之細胞免疫療法
  • 腫瘤學、感染疾病疾病LMP-1/LMP-2標的之細胞免疫療法
  • 腫瘤學、滑薄膜肉瘤XNY-ESO-1/MAGEA4/PRAME/surubibin標的之細胞免疫療法
  • CMD-003
  • CPI-0610
  • CUDC-907
  • entinostat
  • EB病毒疫苗
  • Ferritarg
  • FP-1304
  • FT-1050
  • haNK Program
  • INCB-40093
  • Indimitecan
  • Indotecan hydrochloride
  • Iomab-B
  • ipilimumab
  • ixazomib citrate
  • lirilumab
  • MK-2206
  • mocetinostat
  • 血液系統腫瘤的PD-1/PD-L1阻礙單株抗體
  • 腫瘤學的CD45標的單株抗體複合體
  • NiCord
  • nivolumab
  • NSC-678515
  • Panobinostat
  • pembrolizumab
  • PF-06801591
  • PNK-007
  • procarbazine hydrochloride
  • radretumab
  • 黑色素瘤、何杰金氏淋巴瘤用組換蛋白質
  • resminostat
  • ricolinostat
  • RP-323
  • ruxolitinib phosphate
  • SEL-24B489
  • SL-101
  • SL-501
  • temsirolimus
  • TGR-1202
  • TKM-PLK1
  • TTI-621
  • 鼻咽癌、何杰金氏淋巴瘤用疫苗

何杰金氏淋巴瘤治療藥:開發中產品的最新趨勢

何杰金氏淋巴瘤治療藥:開發暫停的產品

何杰金氏淋巴瘤治療藥:開發中止的產品

何杰金氏淋巴瘤相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿
  • ■附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9095IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape.

Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 25, 27, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 5, 1 and 1 molecules, respectively.

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Overview
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Development
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Assessment
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Companies Involved in Therapeutics Development
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Drug Profiles
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Product Development Milestones
  • Appendix 408

List of Tables

  • Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by 4SC AG, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by AbbVie Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Actinium Pharmaceuticals Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by ADC Therapeutics Sarl, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Affimed GmbH, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Alfa Wassermann SpA, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Alissa Pharma, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Amgen Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Arno Therapeutics Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Celgene Corp, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cell Medica Ltd, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellectis SA, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Celleron Therapeutics Ltd, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellular Biomedicine Group Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Constellation Pharmaceuticals Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cornerstone Pharmaceuticals Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Curis Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Faron Pharmaceuticals Oy, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Incyte Corp, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Kite Pharma Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by MedImmune LLC, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Merck & Co Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Merck KGaA, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Mesoblast Ltd, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Mirati Therapeutics Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Molecular Templates Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by NantKwest Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by NBE-Therapeutics AG, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Pfizer Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Philogen SpA, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rhizen Pharmaceuticals SA, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rich Pharmaceuticals Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Seattle Genetics Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Selvita SA, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Stemline Therapeutics Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Syndax Pharmaceuticals Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Taiwan Liposome Company Ltd, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Theravectys SA, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Trillium Therapeutics Inc, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top